Abstract: In order to board or exit a vehicle, one or a plurality of steps or plates are provided for negotiation of a possible difference of height by a person in a wheelchair entering or getting off between the level of the floor of the vehicle and a platform at a higher or lower level. At least one step or plate is foreseen which is height adjustable, and can be positioned at a position above the floor of the vehicle, below the floor of the vehicle, or at the same level as the floor of the vehicle.

Abstract: In order to board or exit a vehicle, one or a plurality of steps or plates, are provided for a negotiating of a possible difference of height by a person entering or getting off between the level of the floor of the vehicle and a platform at a higher or lower level. At least one step is forseen which is height adjustable and can be positioned at a position above the floor of the vehicle, at a position equal to the level of the floor and/or below the floor, as well.

Abstract: The invention concerns 7-amino-ceph-3-em-4-carboxylic acid compounds of the formula ##STR1## wherein R.sub.1.sup.a represents hydrogen or an amino protective group R.sub.1.sup.A and R.sub.1.sup.b represent hydrogen or an acyl group AC, or R.sub.1.sup.A and R.sub.1.sup.b together denote a bivalent amino protective group, and R.sub.2 represents hydrogen or an organic radical R.sub.2.sup.A which together with the --C(.dbd.O)--O-- grouping forms a protected carboxyl group, or salts such compounds which possess salt-forming groups; these compounds have antibiotic properties.

Abstract: The invention concerns 7.beta.-amino-cepham-3-one-4-carboxylic acid compounds, particularly esters thereof, and the N-substituted, especially N-acylated derivatives of such compounds. They can be used as intermediates, for example, for the manufacture of the corresponding enol ethers and esters, as well as the corresponding 3-unsubstituted 7.beta.-amino-3-cephem-4-carboxylic acid compounds, which show outstanding pharmacological effects.

Abstract: The invention concerns 7.beta.-amino-cepham-3-one-4-carboxylic acid compounds, particularly esters thereof, and the N-substituted, especially N-acylated derivatives of such compounds. They can be used as intermediates, for example, for the manufacture of the corresponding enol ethers and esters, as well as the corresponding 3-unsubstituted 7.beta.-amino-3-cephem-4-carboxylic acid compounds, which show outstanding pharmacological effects.

Abstract: The invention concerns a process for the manufacture of 7.beta.-amino-3-cephem-3-ol-4-carboxylic acid compounds by ring closure of esters of 2-[4-(substituted-thio)-3-acylamino-2-oxoazetidin-1-yl]-3-substituted-amin o-crotonic acids and solvolysing the enamino group in the resulting 7.beta.-acylamino-3-substituted-amino-cephem-4-carboxylic acid esters.

Abstract: The invention concerns a process for the manufacture of 7.beta.-amino-3-cephem-3-ol-4-carboxylic acid compounds by ring closure of esters of 2-[4-(substituted-thio)-3-acylamino-2-oxoazetidin-1-yl]-3-substituted-amin o-crotonic acids and solvolysing the enamine group in the resulting 7.beta.-acylamino-3-substituted-amino-cephem-4-carboxylic acid esters.

Abstract: The invention concerns 7.beta.-amino-cepham-3-one-4-carboxylic acid compounds, particularly esters thereof, and the N-substituted, especially N-acylated derivatives of such compounds. They can be used as intermediates, for example, for the manufacture of the corresponding enol ethers and esters, as well as the corresponding 3-unsubstituted 7.beta.-amino-3-cephem-4-carboxylic acid compounds, which show outstanding pharmacological effects.

Abstract: The invention concerns the decarbonylation of the formyl group in 7-amino-3-formyl-ceph-2-em-4-carboxylic acid compounds and 7-amino-3-formyl-ceph-3-em-4-carboxylic acid compounds by treatment with a platinum metal complex capable of taking up carbon monoxide. Also included are the 7-amino-ceph-2-em-4-carboxylic acid compounds and the 1-oxides of 7-amino-ceph-3-em-4-carboxylic acid compounds; these compounds are used as intermediates.

Abstract: The invention concerns a process for the manufacture of 7.beta.-amino-3-cephem-3-ol-4-carboxylic acid compounds by ring closure of esters of 2-[4-(substituted-thio)-3-acylamino-2-oxoazetidin-1-yl]-3-substituted-amin o-crotonic acids and solvolyzing the enamino group in the resulting 7.beta.-acylamino-3-substituted-amino-cephem-4-carboxylic acid esters.

Abstract: The invention concerns 7-amino-ceph-3-em-4-carboxylic acid compounds of the formula ##STR1## wherein R.sub.1.sup.a represents hydrogen or an amino protective group R.sub.1.sup.A and R.sub.1.sup.b represent hydrogen or an acyl group Ac, or R.sub.1.sup.A and R.sub.1.sup.b together denote a bivalent amino protective group, and R.sub.2 represents hydrogen or an organic radical R.sub.2.sup.A which together with the --C(.dbd.O)--O-- grouping forms a protected carboxyl group, or salts such compounds which possess salt-forming groups; these compounds have antibiotic properties.

Abstract: The invention relates to O-substituted 7.beta.-amino-3-cephem-3-ol-4-carboxylic acid compounds of the formula ##STR1## wherein R.sub.1.sup.a represents hydrogen or an amino protective group R.sub.1.sup.A and R.sub.1.sup.b represents hydrogen or an acyl group Ac, or R.sub.1.sup.a and R.sub.1.sup.b together represent a bivalent amino protective group, R.sub.2 represents hydroxyl or a radical R.sub.2.sup.A which together with the carbonyl grouping --C(.dbd.O)-- forms a protected carboxyl group and R.sub.3 represents an optionally substituted hydrocarbon radical or an acyl group, and to 1-oxides of 3-cephem compounds of the formula I, and also to the corresponding 2-cephem compounds of the formula ##STR2## wherein R.sub.1.sup.a, R.sub.1.sup.b, R.sub.2 and R.sub.3 have the abovementioned meanings, or salts of such compounds with salt-forming groups. 3-Cephem compound of the formula IA, particularly those, in which R.sub.1.sup.a represents an acyl group, R.sub.1.sup.b is hydrogen and R.sub.

Abstract: The invention concerns 7.beta.-amino-cepham-3-one-4-carboxylic acid compounds, particularly esters thereof, and the N-substituted, especially N-acylated derivatives of such compounds. They can be used as intermediates, for example, for the manufacture of the corresponding enol ethers and esters, as well as the corresponding 3-unsubstituted 7.beta.-amino-3-cephem-4-carboxylic acid compounds, which show outstanding pharmacological effects.

Abstract: Antibiotically active compounds derived from rifamycin S or from the corresponding hydroquinone, rifamycin SV, or from derivatives at least partially hydrogenated in positions 16, 17; 18, 19; 28, 29, such as the 16, 17; 18, 19--tetrahydro- or the 16, 17; 18, 19; 28, 29--hexahydro derivatives, which contain in position 3 a free or an aliphatically substituted amino group. The hydrocarbon radicals of the aliphatically substituted amino group can also be interrupted in their carbon chain by heteroatoms and/or be substituted by functional groups.A special group of these new compounds is represented by 3-amino derivatives as defined above, in which the amino group is a particular type of N-aza-cyclo-aliphatic radical unsubstituted by functional groups, and which has, in addition to the antibiotic action against sensitive microorganisms also an antibacterial activity against certain types of resistant microorganisms.

Abstract: The invention concerns a process for the manufacture of 7.beta.-amino-3-cephem-3-ol-4-carboxylic acid compounds by ring closure of esters of 2-[4-(substituted-thio)-3-acylamino-2-oxoazetidin-1-yl]-3-substituted-amin o-crotonic acids and solvolysing the enamino group in the resulting 7.beta.-acylamino-3-substituted-amino-cephem-4-carboxylic acid esters.

Abstract: 7.beta.-Amino-3-cephem-3-cl-4-carboxylic acid compounds of the formula ##STR1## wherein R.sub.1.sup.a represents hydrogen or an amino protective group R.sub.1.sup.A and R.sub.1.sup.b represents hydrogen or an acyl group Ac, or R.sub.1.sup.a and R.sub.1.sup.b together represent a bivalent amino protective group, R.sub.2 represents hydroxyl or a radical R.sub.2.sup.A which together with the carbonyl grouping --C(.dbd.O)-- forms a protected carboxyl group and R.sub.3 represents hydrogen, lower alkyl or a hydroxyl protective group, and 1-oxides of 3-cephem compounds of the formula IA, and the corresponding 2-cephem compounds are prepared in that a compound of the formula ##STR2## wherein R.sub.1.sup.a, R.sub.1.sup.b and R.sub.2.sup.A have the meanings mentioned under formula IA, R.sub.3.sup.o represents lower alkyl or a hydroxyl protective group and Y represents a group which is removed, is treated with a base; also comprised are intermediate products.

Abstract: The invention concerns a process for the manufacture of 7.beta.-amino-3-cephem-3-ol-4-carboxylic acid compounds by ring closure of esters of 2-[4-(substituted-thio)-3-acylamino-2-oxoazetidin-1-yl]-3-substituted-amin o-crotonic acids and solvolyzing the enamino group in the resulting 7.beta.-acylamino-3-substituted-amino-cephem-4-carboxylic acid esters.

Abstract: The invention concerns the decarbonylation of the formyl group in 7-amino-3-formyl-ceph-2-em-4-carboxylic acid compounds and 7-amino-3-formyl-ceph-3-em-4-carboxylic acid compounds by treatment with a platinum metal complex capable of taking up carbon monoxide. Also included are the 7-amino-ceph-2-em-4-carboxylic acid compounds and the 1-oxides of 7-amino-ceph-3-em-4-carboxylic acid compounds; these compounds are used as intermediates.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 denotes optionally substituted phenyl, thienyl, furyl or 1,4-cyclohexadienyl, R.sub.2 represents a free carboxyl group or an esterified carboxyl group which can be split physiologically, R.sub.3 represents hydrogen, lower alkoxy or an optionally substituted methyl group and B represents an optionally substitued six-membered ring with 1 to 3 ring nitrogen atoms, which is bonded to the carbonyl group --C(.dbd.O)-- by one of its carbon atoms, the nitrogen atoms of a monocyclic six-membered ring having 2 nitrogen atoms being either adjacent or separated by two ring carbon atoms, and the salts of such compounds which have a salt-forming group, including the inner salts, for example the 7.beta.-[D(-)-.alpha.-(3,5-Dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-c arboxamido)-phenylacetamido]-cephalosporanic acid, have antibiotic activity.

Abstract: Antibiotically active compounds derived from rifamycin S or from the corresponding hydroquinone, rifamycin SV, or from derivatives at least partially hydrogenated in positions 16, 17; 18, 19; 28, 29, such as the 16, 17; 18, 19-tetrahydro-or the 16, 17; 18, 19; 28, 29-hexahydro derivatives, which contain in position 3 a free or an aliphatically substituted amino group. The hydrocarbon radicals of the aliphatically substituted amino group can also be interrupted in their carbon chain by heteroatoms and/or be substituted by functional groups.A special group of these new compounds is represented by 3-amino derivatives as defined above, in which the amino group is a particular type of N-aza-cyclo-aliphatic radical unsubstituted by functional groups, and which has, in addition to the antibiotic action against sensitive microorganisms also an antibacterial activity against certain types of resistant microorganisms.